24-Hour Crisis Hotline: (877)SAFEGBC or (877)723-3422 Mental Health & Substance Abuse Issues

6502 Nursery Drive, Suite 100
Victoria, TX 77904
Fax: (361)578-5500

Medical Disorders
Basic InformationLookupsLatest News
Another COVID-19 Symptom Joins the List: Mouth RashPets Provide Comfort for 'Ruff' Quarantine TimeYoung Adults May Face Higher Risk for Severe COVID Than ThoughtInfusion of Certain Immune Cells May Help in Severe Coronavirus CasesWill COVID Pandemic's Environmental Benefit Last?Moderna COVID-19 Vaccine 'Promising' After Early TrialCommon Heartburn Drugs May Be Tied to Higher COVID RiskTough Decisions as COVID-19 Causes Cancer Surgery DelaysWhat Jobs Are Toughest on the Knees?Prisoners Nearly 6 Times More Likely to Get COVIDWhat If a COVID-19 Vaccine Arrived and Many Americans Said No?More States Roll Back Reopenings as Coronavirus Cases ClimbRheumatoid Arthritis Treatment Doesn't Harm Lungs: StudyCOVID-19 May Trigger High Blood Sugar, Raising Death Risk: StudyWhat People With Sickle Cell Disease Need to Know About COVID-19Evidence Mounts That TB Vaccine Might Help Protect Against COVID-19New Coronavirus Cases and Deaths Spike Across AmericaHigh-Fiber, Low-Fat Diet May Help People With Ulcerative ColitisRemdesivir May Reduce Deaths, Hasten Recovery for COVID-19 PatientsAHA News: More People Are Dying During the Pandemic – and Not Just From COVID-19Antiviral Drugs Tied to Heart Issue in COVID-19 PatientsMost Survivors of Severe COVID-19 Report Symptoms Many Weeks After 'Recovery'Terrifying Delirium Can Strike Hospitalized COVID-19 PatientsCold War Antiseptic May Be Valuable Germ FighterWith Social Distancing, Schools Should Be Safe to Reopen This Fall, Experts SayU.S. Sees Another Record-Breaking Day of New Coronavirus Cases'Aerosol Boxes' Meant to Protect COVID Health Teams Might Harm Them: StudyAHA News: Where Do New Viruses Like the Coronavirus Come From?Blood Test May Reveal Concussion Severity With Accuracy of Spinal TapIn Many Cases, Hip Replacement Also Eases Back Pain'Broken Heart Syndrome' Has Risen During Pandemic: StudyCoronavirus Fears Kept Many Essential Workers at Home in April: StudyExposure to Iodine in the NICU May Affect Infant Thyroid FunctionA Dangerous Antibiotic-Resistant Bacteria May Now Lurk in U.S. Water, SoilZika May Have Damaged More Infants' Brains Than ExpectedU.S. Air Pollution Still at Deadly Levels, Study FindsCOVID-19 Outbreaks at Meat Processing Plants Are Hitting Minorities HardU.S. Coronavirus Cases Near 3 Million as Hospitals in Sun Belt Fill Up With PatientsAHA News: Months After Infection, Many COVID-19 Patients Can't Shake IllnessCoronavirus Ups Anxiety, Depression in the LGBTQ CommunityMajor Medical Groups Urge Americans to Wear Face MasksBlack Patients Fare Worse After AngioplastyHow Immune System Fights COVID-19 May Be Key to Vaccine SuccessWill the COVID-19 Pandemic Leave a Mental Health Crisis in Its Wake?New U.S. Coronavirus Cases Hit Another HighMultiple Surgeries for Cleft Lip, Palate Won't Cause Major Psychological DamageHIV May Not Worsen COVID-19 OutlookU.S. Coronavirus Hospitalizations Spiking in South, WestAHA News: To Everything There Is a Season, Including Heart DiseaseAsthma, Allergies Plus Pandemic May Pose 4th of July Challenges
Questions and AnswersLinks
Related Topics


Fetroja Approved to Treat Complicated Urinary Tract Infections

HealthDay News
Updated: Nov 15th 2019

new article illustration

FRIDAY, Nov. 15, 2019 (HealthDay News) -- Antibacterial drug Fetroja (cefiderocol) has been approved to treat patients aged 18 years and older with complicated urinary tract infections (cUTIs), the U.S. Food and Drug Administration announced yesterday.

The drug is indicated for patients with limited or no alternative treatment options for cUTI, including kidney infections caused by susceptible Gram-negative microorganisms. Dosage is 2 g of Fetroja every eight hours administered by intravenous infusion over three hours. Dose adjustments are required based on creatinine clearance. Prescription labeling on Fetroja includes a warning for a higher all-cause mortality rate in Fetroja-treated critically ill patients with multidrug-resistant Gram-negative bacterial infections.

Approval of Fetroja was based on safety and efficacy data from 448 patients with cUTI in the APEKS-cUTI study. Symptoms resolved and bacteria were eradicated in 72.6 percent of patients who received Fetroja seven days after treatment completion versus 54.6 percent of patients who received imipenem/cilastatin. Clinical response rates were similar between the two groups of patients.

The cause of the higher mortality rate with Fetroja in critically ill patients with multidrug-resistant Gram-negative bacterial infections is unknown. According to the FDA, some of the deaths were due to worsening or complications of infection or underlying comorbidities. This higher mortality rate was also seen among patients treated for hospital-acquired/ventilator-associated pneumonia, bloodstream infections, or sepsis. The agency noted that the safety and efficacy of Fetroja for treating these types of infections has not been determined.

The most commonly reported adverse reactions with Fetroja included diarrhea, constipation, nausea, vomiting, elevations in liver tests, rash, infusion site reactions, candidiasis, cough, headache, and hypokalemia. Patients who have had severe hypersensitivity to beta-lactam antibacterial drugs should not take Fetroja.

Approval was granted to Shionogi & Co.

More Information